Wagner, J. A., S. A. Williams, and C. J. Webster. 2007. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clinical Pharmacology and Therapeutics 81(1):104–107.

Wang, Y., and J. M. G. Taylor. 2002. A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 58(4):803–812.

Webb, K. S., and G. H. Lin. 1980. Urinary fibronectin—Potential as a biomarker in prostatic-cancer. Investigative Urology 17(5):401–404.

Weir, C. J., and R. J. Walley. 2006. Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Statistics in Medicine 25(2):183–203.

Wittes, J., E. Lakatos, and J. Probstfield. 1989. Surrogate endpoints in clinical trials: Cardiovascular diseases. Statistics in Medicine 8(4):415–425.

Wood, P. H. 1983. Where are we now with radiographic assessment of rheumatoid arthritis? British Journal of Rheumatology 22(3 Suppl):24–33.

Woosley, R. L. 1990. CAST—Implications for drug development—Commentary. Clinical Pharmacology & Therapeutics 47(5):553–556.

Xu, J., and S. L. Zeger. 2001. The evaluation of multiple surrogate endpoints. Biometrics 57(1):81–87.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement